Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy

D. B. Calvo, Y. Z. Patt, S. Wallace, V. P. Chuang, R. S. Benjamin, J. D. Pritchard, E. M. Hersh, G. P. Bodey, G. M. Mavligit

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

Forty‐nine patients with regionally confined recurrent malignancy were treated with intra‐arterial cisdiamminedichloro platinum II in a Phase I‐II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra‐arterial cis‐platinum are discussed.

Original languageEnglish (US)
Pages (from-to)1278-1283
Number of pages6
JournalCancer
Volume45
Issue number6
DOIs
StatePublished - Mar 15 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy'. Together they form a unique fingerprint.

Cite this